The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASCO 2019 | How should hypomethylating agents be used in combination therapy?

Jun 5, 2019

Aref Al-Kali from the Mayo Clinic, Rochester, US, speaks with the AML Global Portal (AGP) during ASCO 2019 about how to optimize the use of hypomethylating agents in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Aref Al-Kali raises many questions within the topic, including whether azacitidine and decitabine should be used as single agents, or in combination with newer agents such as venetoclax. One particular topic that was of interest to the ASCO audience during Aref Al-Kali's talk during ASCO, was how to use fewer drugs, such as low dose azacitidine or decitabine, in patients with low-risk MDS.

How should hypomethylating agents be used in combination therapy?